DES(1-3) IGF-1 description
Insulin Like Growth Factor (IGF)-1 (4-70), otherwise known as IGF-1 DES, produced in E. coli, is a single, non-glycosylated, polypeptide chain containing 67 amino acids and having a molecular mass of 7,372 Da. In vitro studies demonstrate that at equal doses DES (1-3) IGF is ten times more potent than IGF-1 at stimulating hypertrophy and proliferation in cultured cells. It is likely generated through post-translational modification in the sequence of circulating mature IGF-1 via protease action.
IGF-1 mediates many of growth-promoting effects of GH
IGF-1 DES is a cleaved form of IGF-1 and contains amino acids 4-70. This structure has allowed the effects of the IGF-1 protein to be amplified in the more stable form of the DES 1,3 molecule peptide protein fragment of Insulin-like growth factor 1. The IGF-1 DES, or insulin-like growth factor DES, comes from the IGF-1 family of peptides that play important roles in mammalian growth and development. IGF1 mediates many of the growth-promoting effects of growth hormone and IGF-1 DES, although shorter, pacts an equal amount of physiological altering protein physical changes. Early studies showed that growth hormone did not directly stimulate the incorporation of sulfate into cartilage, but rather acted through a serum factor, termed ‘sulfation factor,’ which later became known as ‘somatomedin’ or IGF-1 and more recently through truncation, DES IGF-1.
DES(1-3) IGF-1 benefits and effects
- DES(1-3) IGF-1 supports the overall regeneration of the whole body (including internal organs), increased cell repair
- DES(1-3) IGF-1 has a strong anabolic effect, promoting muscle growth, strength and performance
- DES(1-3) IGF-1 has the ability to induce muscle hyperplasia – the growth of new muscle cells
- DES(1-3) IGF-1 may reduce the risk of heart and cardiovascular disease
- DES(1-3) IGF-1 helps increase bone density
DES(1-3) IGF-1 possible side effects
- Possible association of IGF-1 with certain forms of cancer development (however, the studies performed are often unclear and very often have conflicting or very different results)
- Risk of diabetes (studies performed are also often unclear and contradictory at this point)
- Low blood sugar
DES(1-3) IGF-1 dosage
Optimal dose of DES(1-3) IGF-1 is often reported as 50-150 mcg of DES(1-3) IGF-1, intramuscularly directly into muscle where an anabolic effect is required, periods of from 4 to 12 weeks of use are reported